Bristol-Myers Squibb (BMY)
$46.98 1.23 (2.69%)
18:47 EDT BMY Stock Quote Delayed 15 Minutes
Previous Close $46.98
Market Cap 76.79B
PE Ratio 82.42
Volume (Avg. Vol.) 9.63M
Day's Range 45.78 - 47.06
52-Week Range 42.48 - 63.69
Dividend & Yield 1.60 (3.41%)
BMY Stock Predictions, Articles, and Bristol-Myers Squibb News
- From InvestorPlace
- From the Web
Bristol-Myers Squibb stock touched a multi-year low last month. But the BMY stock price is cheap enough now to take on real risks.
Political pressures regarding drug pricing and Bristol-Myers’ disappointing clinical trails have contributed to a disappointing performance for BMY stock. Still, much of this bearishness could be priced in already.
BMY stock may continue to bounce around, but the months-long selloff is now slowing because Bristol-Myers Squibb is still thriving.
Stock were hit on Thursday as investors try to parse through a deluge of earnings results. Here's what moved the stock market today.
Bristol-Myers Squibb earnings for the second quarter of the year have BMY stock on the move Thursday after it beat estimates.
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?
These 10 stocks don't quite qualify as "set it and forget it" plays. All have some degree of risk. But the risks seem worth taking for the potential rewards, which include near-term income, longer-term growth, and potential capital appreciation.
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
AbbVie is buying Allergan, FedEx and Blackberry are reporting earnings and Microsoft is on the move. Here are our top stock trades.
The stock charts of EA, AAP and MGM have run through the technical trading wringer in front of today's action.
Bristol-Myers Squibb, Celgene, Caesars Entertainment, Match Group and New Relic are our top stock trades for Tuesday.
Bristol-Meyers Squibb news for Monday has BMY stock taking a beating after announcing a delay to its merger deal with Celgene.
MMM stock has fallen 25% in the past six weeks since announcing weaker-than-expected Q1 earnings. 3M stock has been weak since then.
Buy Pfizer stock on this current round of weakness. The underpinnings are bullish for 2020 and beyond.
Bristol-Myers Squibb earnings for the first quarter of 2019 have BMY stock up Thursday on an earnings per share and revenue beat.
Bristol-Myers Squibb’s (NYSE:BMY) stock price has fallen by over 35% over the last three years, despite a growth in revenues, margins, and earnings. The decline can be attributed only to contraction in the price to earnings multiple. In this note we discuss the factors that led to the stock price...
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!